Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Recommendation of “Hold” from Analysts

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been given a consensus recommendation of “Hold” by the six research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $3.2250.

Several research firms have weighed in on LXRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th.

Insider Activity

In other news, Director Invus Global Management, Llc purchased 1,538,462 shares of the stock in a transaction dated Monday, February 2nd. The stock was acquired at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the completion of the acquisition, the director directly owned 1,538,462 shares in the company, valued at $2,000,000.60. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 13.90% of the stock is owned by corporate insiders.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Lexicon Pharmaceuticals by 7.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company’s stock valued at $12,855,000 after acquiring an additional 670,838 shares during the last quarter. Millennium Management LLC grew its position in shares of Lexicon Pharmaceuticals by 25.9% in the fourth quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company’s stock valued at $5,545,000 after purchasing an additional 991,073 shares during the period. UBS Group AG increased its stake in Lexicon Pharmaceuticals by 752.1% in the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock valued at $3,458,000 after purchasing an additional 2,654,315 shares during the last quarter. Geode Capital Management LLC increased its stake in Lexicon Pharmaceuticals by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 2,500,022 shares of the biopharmaceutical company’s stock valued at $2,876,000 after purchasing an additional 102,099 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Lexicon Pharmaceuticals in the third quarter valued at $3,240,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Trading Up 15.2%

Shares of LXRX opened at $1.52 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $1.83. The stock has a market cap of $552.47 million, a price-to-earnings ratio of -8.00 and a beta of 0.98. The firm has a 50 day simple moving average of $1.29 and a 200-day simple moving average of $1.30.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.